1. Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines
- Author
-
Michał Otręba, Jared D. Warncke, and Monika Pajor
- Subjects
0301 basic medicine ,Perphenazine ,Skin Neoplasms ,Cell Survival ,Antineoplastic Agents ,Prochlorperazine ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Cell Line, Tumor ,medicine ,Humans ,Viability assay ,Amelanotic melanoma ,Melanoma ,Pharmacology ,Microphthalmia-Associated Transcription Factor ,Dose-Response Relationship, Drug ,Monophenol Monooxygenase ,business.industry ,General Medicine ,medicine.disease ,Microphthalmia-associated transcription factor ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer cell ,Cutaneous melanoma ,Cancer research ,business ,Antipsychotic Agents ,medicine.drug - Abstract
Cutaneous melanoma is least common (only about 1% of skin cancers) but is the deadliest malignant tumor. Moreover, amelanotic types of melanoma are very difficult for clinical diagnosis. The standard therapy can cause a lot of side effects, e.g., nausea, vomiting, and headaches, which means that novel and effective strategies are required. Interestingly, phenothiazine derivatives possess sedative, antiemetic, and anticancer activity. Our goal was to determine the effect of perphenazine and prochlorperazine on cell viability, motility, microphthalmia-associated transcription factor (MITF) and tyrosinase content in melanotic and amelanotic melanoma cells. The viability of C32 and COLO829 melanoma cells was evaluated by the WST-1 colorimetric assay; impact on motility of human melanoma was performed by wound-healing assay, while tyrosinase and MITF content were determined by Western blot. In the present study, we explore the anticancer effect of perphenazine and prochlorperazine in human melanotic (COLO829) and amelanotic (C32) melanoma cells concluding that prochlorperazine inhibits cell viability in a concentration-dependent manner, impairs motility, and decreases tyrosinase and MITF amounts. Moreover, the analyzed drugs decrease/increase MITF amount depending on the type of melanoma. We demonstrated that the decrease of MITF and tyrosinase protein induces motility inhibition of C32 cells, which suggests the ability of those drugs to restore cancer cell sensitivity to treatment. The ability of prochlorperazine to contain the spread of the amelanotic melanoma in vivo may be helpful in the development of a new and effective antimelanoma therapies.
- Published
- 2019